For low-risk PC, the recommended treatment option is active surveillance using PSA [15], but curative options, such as radical prostatectomy (RP), external beam radiotherapy (RT), and low-dose-brachytherapy, can be used [12]. This evidence concerns the gene KLK3 and pachyonychia congenita.